Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss treatment options for a patient who has developed new brain lesions while on alectinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Author: Editor
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using alectinib for a DCTN1 ALK fusion. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using cabozantinib, and its potential side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using off-label treatments. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses identifying and treating NRG1 fusions in NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss RNA testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.
By. Naval Daver, MD Date: January 12, 2024 Introducing Naval Daver, a faculty member specializing in MD Anderson Cancers in Houston, Texas. As one of the co-chairpersons at a significant conference, Naval values the enriching experience it has offered. During Naval’s presentation, the focus centered on innovative nano-crack-based combination approaches. Specifically, the exploration of novel combinations involving aneroclax with three distinct antibodies—id age in habits, three d one twenty-three antibodies, and three forty-seven antibodies—revealed promising outcomes. These combinations showcased improvements in response rates and survival, indicating optimized durations and dosing for aneroclax and targeted therapy. REGISTER NOW TO JOIN US AT THESE…
By: Parrish Phimes, Date: January 12, 2024 Parrish Phimes, a professor of Intology at the University of Oxford and affiliated with the Oxford University NHS Trust, recently presented insights during an academic gathering. In the conference, Dr. Phimes explored the molecular changes occurring in air cells leading to leukemia, elucidating the underlying mechanisms. Among the aspects of his presentation was an approach to identifying patients likely to respond well or poorly to treatment, specifically chemotherapy and transplantation. Dr. Phimes emphasized the use of genetic changes to categorize patients, distinguishing those expected to have favorable outcomes from those facing challenges in their…
By: Pramilla Krishnamurthy, MD Date: January 12, 2024 Pramilla Krishnamurthy, md, a consultant hematologist at King’s College Hospital in London, engaged in a comprehensive discussion during a recent conference. The focus of her discourse was to scrutinize potential inequities in outcomes for patients diagnosed with AML (Acute Myeloid Leukemia). Dr. Krishnamurthy delved into the intricate interplay of factors contributing to these differential outcomes, highlighting disease biology as a primary determinant. She emphasized the multifaceted nature of the issue, considering variables such as age, with particular attention to teenagers and young adults who might face comparatively worse outcomes. Dr. Krishnamurthy also explored…
By: Priyanka Meta Date: January 11, 2024 Priyanka Meta, a meteorology consultant associated with the University Hospitals of Bristol and Western Managers in the UK, recently presented at a conference on the rare disease BPDCN, also known as plastic plasma cytodendritic cell leukemia neoplasm. Specializing in myeloid diseases, Priyanka discussed historical treatments, challenges, and recent developments in managing BPDCN. During her presentation, she highlighted treatment advances, including Debla Holmes and Degrasse therapies, considered significant in managing the disease. Priyanka also discussed recent developments aimed at improving outcomes for patients with this ailment. REGISTER NOW TO JOIN US AT THESE UPCOMING…
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the integration of circulating tumor DNA (ctDNA) and Minimal Residual Disease (MRD) assessment as essential elements in shaping medical therapy decisions. In Dr. Mchayleh’s perspective, leveraging ctDNA and MRD can serve as a determinant in adjusting the intensity of treatment protocols.During his address at MDAS, Dr. Mchayleh highlights the potential of ctDNA as a tool for MRD monitoring and early recurrence detection. Expressing concern that this approach is currently underused, he stresses the importance of incorporating ctDNA and MRD analyses at the early stages of treatment.…
In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual Disease (MRD). Dr. Mchayleh discusses the application of MRD in colorectal and breast cancer, highlighting its ability to predict early recurrence before radiologic signs appear, as evidenced in various trials. He emphasizes the sensitivity of MRD testing in detecting early recurrence.Dr. Mchayleh advocates for a proactive approach to using MRD in the neoadjuvant setting for early breast cancer. He envisions a shift where MRD not only predicts treatment responses but also influences therapeutic strategies based on MRD outcomes, particularly gauging the clearance of plasma during…
<blockquote class=”twitter-tweet” data-media-max-width=”560″><p lang=”en” dir=”ltr”>Cybertruck towing 3000lbs to the dunes was a breeze! <a href=”https://twitter.com/Tesla?ref_src=twsrc%5Etfw”>@Tesla</a> <a href=”https://twitter.com/cybertruck?ref_src=twsrc%5Etfw”>@cybertruck</a> <a href=”https://twitter.com/elonmusk?ref_src=twsrc%5Etfw”>@elonmusk</a> <a href=”https://t.co/x2esrlBbWP”>pic.twitter.com/x2esrlBbWP</a></p>— Arash Malek (@MinimalDuck) <a href=”https://twitter.com/MinimalDuck/status/1744155632427745454?ref_src=twsrc%5Etfw”>January 8, 2024</a></blockquote> <script async src=”https://platform.twitter.com/widgets.js” charset=”utf-8″></script>
<div id=”cincopa_6410e0″>…</div><script type=”text/javascript”> var cpo = []; cpo[“_object”] =”cincopa_6410e0″; cpo[“_fid”] = “AYLAZJfyDwAd”; var _cpmp = _cpmp || []; _cpmp.push(cpo); (function() { var cp = document.createElement(“script”); cp.type = “text/javascript”; cp.async = true; cp.src = “https://rtcdn.cincopa.com/libasync.js”; var c = document.getElementsByTagName(“script”)[0]; c.parentNode.insertBefore(cp, c); })(); </script> …
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s Research Executive Committee, is scheduled to participate in an upcoming interview. During this discussion, he will provide insights into his recent study, titled “Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL / SLL in the US Community Setting.”In the interview, Dr. Andorsky will offer an overview of the study, highlighting changes in the treatment landscape of BTK inhibitors for CLL / SLL. Specifically, he will discuss variations in the use…
Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How Can We Manage High-Risk Hematologic Malignancies in the Community?” The study investigates the impact of integrating novel agents, BiTe therapy, CAR-T, and transplantation into the standard of care for hematologic malignancies in community settings.Dr. Patel-Donnelly shares insights based on her experience, discussing the challenges and opportunities associated with implementing advanced therapies in local cancer care. The educational session emphasizes the need to address access issues for patients with hematologic malignancies in the community, focusing on specific diagnostic, supportive, and treatment challenges in acute leukemia, high-grade…
In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL), Dr. Brian Hill, MD, PhD, stands at the forefront to discuss the findings of the ZUMA-2 and ZUMA-18 studies. The ZUMA-2 study reported a median overall survival (OS) of 46.4 months with brexu-cel, showcasing its efficacy in patients with relapsed/refractory MCL and a complete response (CR). Dr. Hill will explore the implications of these findings, contributing to the evolving landscape of CAR T-cell therapy for MCL. Moreover, he will discuss considerations surrounding the durability of response observed in these patients, adding a dimension to the…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy. The research indicates comparable response rates in Daratumumab-naïve (DN) and Daratumumab-refractory (DR) patients, with a notable difference in median overall survival (OS). The study explores potential reasons for the higher OS in the DN group and discusses the impact of these findings on treatment decisions for highly refractory multiple myeloma patients. The research also notes similar treatment-related toxicities between DN and DR groups but observes a higher rate of rehospitalization…
John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology Department at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, VIC, Australia, conducted a groundbreaking Phase 1 study on BGB-16673, a pioneering Bruton tyrosine kinase (BTK) degrader. The focus of this study was on patients grappling with relapsed or refractory B-cell malignancies, particularly those who had faced disease progression despite undergoing treatment with BTK inhibitors. The study aimed to delve into the unique mechanism of action of BGB-16673, specifically highlighting the chimeric degradation activating compound (CDAC) structure responsible for BTK degradation. Understanding this…
Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone Marrow Transplant and Cellular Therapies. The study, “Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies,” led by Dr. Varshavsky-Yanovsky, delves into the efficacy and safety of elranatamab in Black or African American patients grappling with relapsed/refractory multiple myeloma (RRMM). This investigation explores critical metrics such as the overall response rate (ORR) and median duration of response (DOR). Notably, elranatamab exhibited a promising ORR of 58.3% and a median DOR of 18.4 months among…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL) patients. The study focuses on the safety and efficacy of combining Sonrotoclax, a second-generation BCL2 inhibitor, with Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor. Preliminary results suggest outcomes, with a focus on responses, tolerability, and safety.The combination of Sonrotoclax and Zanubrutinib presents an advancement in the treatment landscape for TN-CLL/SLL patients. Compared to existing treatments, this combination demonstrates potential advantages, including a safety profile with manageable treatment-emergent adverse events. Dr. Tam explores aspects…
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology at SA Pathology in Adelaide, Australia. In collaboration with his colleague, Chris Hahn, MD, who heads the Molecular Pathology Research Laboratory, Dr. Scott shares insights into a groundbreaking study during an interview. The research stemmed from a case involving a family with thrombocytopenia and neutropenia, where the mother developed acute myeloid leukemia and myelodysplastic syndrome.Their investigation led to the discovery of a novel predisposition gene, ERG, associated with bone marrow failure and hematological malignancies. The study uncovered a missense mutation in the ERG gene among…
Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic Children’s, conducted a study on AsCas12a gene editing with EDIT-301 for severe Sickle Cell Disease (SCD) and transfusion-dependent β-thalassemia (TDT). The research aimed to evaluate the efficacy of this approach in achieving normalization of hemoglobin levels and increased production of fetal hemoglobin (HbF) in affected patients.The results of EDIT-301 in patients with severe SCD and TDT contribute to the growing field of gene-edited therapies for hemoglobinopathies. This novel approach, targeting HBG1/2 promoters, has potential for outcomes in patients with these conditions, advancing our understanding of…
Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center, leads research focused on improving the outcomes of patients with hematologic malignancies. The study, Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry, delves into the real-world outcomes of brexucabtagene autoleucel, known as brexu-cel, for adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-cell ALL).Intriguingly, the study reveals that a substantial 91% of the patients included would have been ineligible for the ZUMA-3 trial. This raises important questions about…
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the focus is on investigating the efficacy of Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting.The study delves into the real-world treatment patterns and outcomes of patients grappling with relapsed/refractory DLBCL who have undergone tafasitamab treatment within community oncology settings. A key objective is to draw comparisons between these findings and the results observed in the L-MIND clinical trial.Dr. Feinberg’s research particularly emphasizes a racially and ethnically diverse patient population, with a notable representation from typically underrepresented…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina, discussed a multicenter study focusing on the toxicity and efficacy outcomes associated with Teclistamab in patients above the age of 70 with relapsed refractory multiple myeloma.The retrospective analysis included nearly 100 patients, with around one-third of them aged 70 or above. Dr. Hashmi highlighted the challenges faced by older patients, such as compromised physical performance status, organ dysfunction, renal issues, and other high-risk disease features. Over a median follow-up of approximately three and a half months, the study revealed comparable safety and efficacy outcomes between…
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study titled “Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412).”This Phase II study investigated the efficacy and safety of combining immune checkpoint blockade with the CD30-targeting antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Classic Hodgkin lymphoma (cHL).The study’s importance lies in its approach to addressing the challenges of cHL treatment. By combining immune checkpoint inhibitors (Ipilimumab and Nivolumab) with brentuximab vedotin,…
In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a study on predicting progression-free survival (PFS) in early-stage Hodgkin lymphoma (E-HL). Dr. Evens, a seasoned researcher and clinician, will provide insight into the E-HIPI model, which identifies factors such as nodal location, sex, and key continuous variables as essential in prognosticating PFS.When asked for a brief overview of the study, Dr. Evens will share insights into the research’s significance and potential implications for oncology. Regarding the E-HIPI model, he will elaborate on how factors like nodal location, sex, and key continuous variables contribute to predicting…
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics in pediatric ALL patients. The research aims to predict long-term responses to anti-CD19 CAR T cells by analyzing gene expression profiles. Dr. Melenhorst reveals a cytogram profile linked to B cell replacement, a key remission biomarker. The interview explores correlations in CAR T cells’ functionality, emphasizing the potential for manipulation to enhance efficacy. Insights from a mouse model underscore the importance of the type 2 pathway in sustaining remission, offering perspectives for CAR T therapy development.
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone. The discussion covered the clinical significance of achieving minimal residual disease (MRD) negativity, with Zandra correlating the depth of response to long-term outcomes. She expressed cautious optimism for the high-risk patient population, highlighting the need for extended follow-up. Safety and tolerability considerations were addressed, with Zandra acknowledging numerical imbalances in deaths and emphasizing the importance of awaiting further survival results. ASH 2023 witnessed an…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center, University of Miami, engaged in a discussion about the final analysis of the Sinterra study. The study, a randomized phase two trial, aimed to assess the efficacy and safety of daratumumab monotherapy in patients with intermediate or high-risk smoldering multiple myeloma.Dr. Landgren outlined the international multicenter nature of the trial and its objective to investigate whether daratumumab could delay or prevent the progression from smoldering myeloma to multiple myeloma.
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi, a medical doctor and lymphoma specialist at Memorial Sloan Kettering in New York, engaged in a conversation.Navigating the pronunciation of a treatment, Dr. Falchi provided an overview of Mosunetuzumab’s role as a first-line therapy for high tumor burden follicular lymphoma, based on the initial results from a multicenter phase 2 study.Dr. Falchi unfolded the narrative behind the study, emphasizing its roots in addressing the limitations of traditional chemotherapy. He highlighted the study’s optimism, revealing Mosunetuzumab’s high deliverability and patient tolerance. The efficacy results were promising,…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown Lombardi Comprehensive Cancer Center at MedStar Health, provided details about a study focused on the time to achieve platelet count response after intravenous Fc-gamma receptor antagonist (Efgartigimod) in adults with primary immune thrombocytopenia.This phase three multicenter double-blind placebo-controlled randomized clinical trial involved multiple countries and targeted adult patients aged 18 or older diagnosed with ITP for a minimum of three months. Dr. Broome explained that these patients had failed at least one therapeutic intervention and were either not responding to their second intervention or had…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical doctor and professor of medicine at Stanford University School of Medicine, shared captivating insights into the transformative landscape of lymphoma treatment during an interview. The discussion centered around the pivotal TRANSFORM study, introducing Lysocabtagene maraleugel as a second-line therapy for large B cell lymphomas resistant to frontline treatments. Dr. Alizadeh eloquently elaborated on the trial’s resounding success, emphasizing its profound shift towards personalized therapies and the abandonment of traditional methods like high-dose chemotherapy and transplantation. The interview seamlessly transitioned into a sub-study, exploring the role…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical doctor and associate professor of hematology from the University of Florence Medical School in Italy, engaged the audience in a discussion about the Phase 3 Medalist study.Dr. Santini commenced her presentation by providing a comprehensive overview of the Medalist trial initiated in 2016. This clinical investigation focused on assessing the response to Luspatercept, an active erythroid maturation agent. The study specifically targeted lower-risk myelodysplastic syndromes (MDS) patients with transfusion dependence who were refractory or ineligible for conventional erythropoietic stimulating agents.The trial involved the administration of…
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers, part of the U.S. Oncology Network, for a discussion about a phase two study on the outpatient administration of Teclistamab, a bispecific antibody targeting BCMA in patients with multiple myeloma. Dr. Rifkin explains that the study aims to bring new classes of myeloma drugs into the clinic and community more practically. Teclistamab, being the first bispecific antibody released for multiple myeloma, initially mandated hospitalization due to concerns about cytokine release syndrome (CRS) and neurologic dysfunction. The study seeks to introduce…
By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director for the Comprehensive Breast Cancer Program at Cleveland Clinic, shares insights into a study focusing on fertility preservation and assisted reproductive technologies in breast cancer patients who interrupt endocrine therapy to attempt pregnancy.Dr. Moore discusses the eligibility criteria for women in the study, emphasizing factors such as age, stage of breast cancer, and duration of adjuvant endocrine therapy. The study, aimed at assessing the short-term safety of interrupting endocrine therapy for pregnancy, explores outcomes related to assisted reproductive technology and…
By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of triple-negative breast cancer (TNBC), will provide answers to questions during the interview. The discussion will cover the significance of evaluating immune landscapes in TNBC, the use of technologies such as NanoString IO360 and Digital Spatial Profiling, the association between immune-related proteins and different landscapes, the exploration of the PI3K-Akt signaling pathway, and the implications of single-cell sequencing findings on targeted therapies. Dr. Chumsri’s insights aim to offer objective perspectives on understanding TNBC and guiding potential treatment strategies.
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill. Graciously taking the time to engage in conversation, Allen extended his gratitude to Dr. Abdou for joining the discussion.In their exchange, the focus shifted to the intricate realm of medical practice, specifically exploring the practice patterns associated with the sequential use of antibody drug conjugates after antibody drugs. Dr. Yara Abdou delved into the complexities of this topic, shedding light on the challenges faced by providers in sequencing these drugs due to the yet-to-be-fully-understood efficacy…
By: Ibrahim Aldoss, MD – City of HopeDate: 12/11/2023Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at McMaster University, shedding light on the groundbreaking findings from the phase three basis trial concerning the anti-tissue factor pathway inhibitor, Marstacimab. The conversation delves into the study’s design and outcomes, focusing on a cohort of patients with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.Dr. Matino provides a comprehensive overview of the study, detailing the observational phase, loading doses, and subsequent treatment phases involving Marstacimab. The emphasis is on the subcutaneous administration of the drug, representing a pivotal advancement in the…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical doctor and oncologist from the Cleveland Clinic Cancer Center. In this discussion, Allen introduces the focus—the Phase 1 trial of the Alpha-Lactalbumin vaccine in high-risk operable triple-negative breast cancer (TNBC) patients and those with a genetic predisposition to TNBC.Dr. Budd elaborates on the primary objectives of the trial, emphasizing the critical role of determining the appropriate vaccine dosage for future applications. The trial evaluates toxicity, primarily manifested as local injection site reactions, and measures immune responses through Alispot assays. The…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor, professor of medicine, and associate chief division hematology, oncology, and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh.In the interview, Allen queries Dr. Brufsky about the real-world effectiveness of Palbociclib, or palbociclib, in combination with aromatase inhibitors for metastatic breast cancer patients with cardiovascular disease. Dr. Brufsky delves into the key findings of the study, highlighting the analysis of patients who were not part of clinical trials, and emphasizing the significance of real-world evidence.The study, known…
Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in breast cancer research.Regarding groundbreaking findings or emerging trends at SABCS 2023, Dr. Mchayleh discussed studies potentially impacting clinical practices in breast cancer management, including novel therapeutic approaches and advancements in targeted therapies.In the area of cutting-edge technologies, Dr. Mchayleh addressed abstracts on precision medicine, genomics, and other innovative approaches in breast cancer research.The conversation then turned to a special feature on Minimal Residual Disease (MRD) testing. Dr. Mchayleh answered questions on the utility of MRD testing and its significance in…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical Director of Hematology Research at the Sarah Cannon Research Institute.Phase 3 Elevate TN trial, a focus of Sharman’s work. The trial, designed for previously untreated chronic lymphocytic leukemia patients, included three arms: a control arm with Obinutuzumab chlorambucil, and two experimental arms with either acalabrutinib monotherapy or a combination of acalabrutinib with obinutuzumab. Sharman reveals that the study resulted in FDA approval for acalabrutinib in previously untreated patients.During the discussion, Sharman unveils key findings from the six-year follow-up study. Notably,…
Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast cancer immunotherapy. Alina Hamilton, a postdoctoral research associate in the cancer control education program at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, shared insights on her work.Motivated by the alarming 41 percent higher breast cancer mortality rate among black women, Hamilton explored Survivin as a potential immunotherapy target. Survivin, a protein in the inhibitor of the apoptosis pathway, showed associations with aggressive tumor features, especially in breast cancer. Despite smaller and less diverse previous studies, Hamilton…